Microbio announced that “Herbiron” has obtained TFDA drug approval, the second approval after Chemo Young in 2011. Herbiron is an oral botanical drug combination designed to improve primary dysmenorrhea and iron-deficiency anemia. Herbiron is a proprietary drug developed by the Microbio in accordance to international drug development regulations and received new drug approval from the Taiwanese Food and Drug Association (TFDA).
Microbio aims to launch and maximize the market potential of Herbiron in the second half of the year. In order to meet the potential market demand, the board of Microbio has agreed to implement cash capital increase for 1 billion TWD, and establish a new manufacturing plant.
The Chairman of Microbio, Dr. Willie Lin said in a statement that up to 5 million of Taiwanese women experience various degree of discomfort and associated pain. Sixty-four percent of these women would choose to use over-the-counter painkiller for their pain management despite the potential side effects such as stomach upsets, ulcers and nausea. The clinical data shows therapeutic efficacy of “Herbiron” significantly alleviate menstrual pain (*p=0.0004) and elevate serum hemoglobin (*p<0.0001).
Herbiron will be classified as an Over-the-Counter drug. To help address the pain management for women, starting from November 2014, “Herbiron” is available at local pharmacies. Microbio elected not to apply for Taiwanese Healthcare reimbursement.